Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06366113

Time of Exercise Re-training With Chronic Obstructive Pulmonary Disease (COPD)

Effect of Time of Exercise Re-training on Functional Capacity in Individuals With Chronic Obstructive Pulmonary Disease (COPD)

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
90 (estimated)
Sponsor
Michaël RACODON · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

Pulmonary rehabilitation (PR) is an effective intervention for reducing hospital readmissions, secondary events, and mortality in patients with respiratory pathologies. The program should not be improved by introducing new subjects such as circadian rhythm.

Detailed description

Respiratory diseases are a leading cause of death in developed countries. To avoid complications and recurrences, secondary prevention in patients with respiratory diseases is essential. Pulmonary rehabilitation (PR) is a well-established and effective treatment that is supervised by medical professionals and conducted in dedicated centres. It has been shown to reduce hospital readmissions, secondary events, and patient mortality. The timing of reconditioning is crucial. Previous studies have indicated that training times affect strength and power gains. Additionally, the time of day for training can significantly impact progress in aerobic capacity. Disturbances to the biological clock can have consequences for people with respiratory pathologies, particularly an alteration in muscular function. Therefore, studying the temporal specificity of exercise re-training in patients with respiratory diseases is of interest.

Conditions

Interventions

TypeNameDescription
OTHERPulmonary rehabilitationPulmonary rehabilitation includes : * Exercise re-training with resumption of physical activities * therapeutic patient education

Timeline

Start date
2024-01-02
Primary completion
2024-01-02
Completion
2026-07-01
First posted
2024-04-15
Last updated
2026-01-12

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT06366113. Inclusion in this directory is not an endorsement.